Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): Results of an open-label randomized controlled trial.

Valliappan MuthuRatnakara Rao GogineniRitesh AgarwalKuruswamy Thurai PrasadInderpaul Singh SehgalSahajal DhooriaAshutosh N AggarwalShivaprakash Mandya RudramurthyHarkant SinghMandeep GargArunaloke Chakrabarti

Published in: Mycoses (2023)

Adjunctive NAB was safe but did not improve overall response at 6 weeks. A different dosing schedule or nebulized liposomal amphotericin B may still need evaluation. More research is needed to explore other treatment options for PM.

Keyphrases

randomized controlled trial
study protocol
pulmonary hypertension
particulate matter
air pollution
heavy metals
phase iii
advanced non small cell lung cancer
gestational age
tyrosine kinase
replacement therapy